

LP Shunt, the Treatment of Choice in Idiopathic Intracranial Hypertension. (A 5 Years Experience at Lahore General Hospital, Lahore)

AMIR AZIZ, YASER-UD-DIN, MUHAMMAD IRFAN

Bashir Ahmed, Tariq Salahuddin

Department of Neurosurgery Unit II, Lahore General Hospital, Lahore

ABSTRACT

Objective: The history, diagnosis, and therapy of idiopathic intracranial hypertension (IIH) are reviewed. Theories of pathogenesis are considered, the clinical presentation is described, and potential diagnostic and therapeutic challenges are explored. Keeping in view all these things efficacy of L.P Shunt is observed.

Material and Methods: A total of 35 patients were diagnosed as IIH according to the Modified Dandy's criteria in our department from August 2007 to October 2012. An extensive literature review of IIH and related conditions was performed. The history of and rationale for the diagnosis and medical and surgical approaches to treatment are reviewed. Outcome of the patients' with L.P shunt is observed.

Study Design: Prospective and analytic study.

Results: LP shunt addresses the cause of both headache and papilloedema more directly by effecting a global reduction of intracranial pressure. All patients underwent clinical, imaging, and CSF manometry evaluations. All patients showed failure or noncompliance to medical treatment and necessitated placement of an LP shunt. Among 35 patients who underwent LP shunt placement for IIH, 14 (40%) patients had severe and fulminant opening CSF pressures with values of more than 400 mm H₂O. while in 21 (60%) patients opening CSF pressure was 260 to 400 mm H₂O. symptoms of headache and papilloedema and visual obscuration improved in most of the patients. Shunt complications included two (0.7%) cases of shunt dislodgement and one (0.35%) case of shunt over drainage. Multiple potential contributing causes of intracranial hypertension must be excluded. On the basis of the advantages and disadvantages of different treatment modalities, we found L.P Shunt to be more effective and advantageous.

Conclusion: Idiopathic intracranial hypertension is the diagnosis of exclusion. Medical therapy has a very little role in relieving signs and symptoms of this disease. L.P Shunt should be the treatment option in IIH.

Key Words: Lumboperitoneal shunt, Headache, Idiopathic intracranial hypertension, Papilloedema.

Abbreviations: IIH = Idiopathic Intracranial Hypertension, LP = Lumboperitoneal, CSF = Cerebrospinal fluid, ICP = Intracranial pressure, H₂O = Water.

INTRODUCTION

Idiopathic intracranial hypertension (IIH) was originally described by Quincke in 1893. He reported several cases of increased intracranial pressure (ICP) without a brain tumor. Nonne described the syndrome more fully and coined the term *pseudotumor cerebri* in

1904. In 1937, Dandy described 22 patients with increased ICP without brain tumor. In 1955, Foley attempted to simplify the nomenclature by describing this condition as *benign intracranial hypertension*. However, in view of the potential for devastating loss of vision associated with papilloedema, Corbett and Tho-

mpson removed the adjective “benign” and substituted “idiopathic.”

Idiopathic intracranial hypertension denotes the condition of increased ICP without an obvious underlying brain pathological condition (and no evidence of venous thrombosis).

The diagnosis of the idiopathic intra cranial hypertension is based on the Dandy’s criteria being modified by Smith in 1985. Dandy originally described the presence of symptoms of increased ICP, documented cerebrospinal fluid (CSF) pressures of 250 to 550 mm H₂O (18.11 to 39.85 mmHg) with normal CSF findings and excluded the possibility of brain tumors with ventriculography.

| |
|---|
| Modified Dandy Criteria for Idiopathic Intracranial Hypertension |
| <p>Symptoms of increased ICP (headaches, nausea, vomiting, transient visual obscurations, or papilloedema).</p> <p>No localizing findings in neurological examinations (except for false localizing signs such as abducens or facial palsies) Awake and alert patient.</p> <p>Normal CT / MRI findings without evidence of dural sinus Thrombosis.</p> <p>ICP of 250 mm H₂O (18.11 mmHg) with normal cerebrospinal fluid cytological and chemical findings.</p> <p>No other cause of increased ICP found</p> |
| <p>Adapted from Digre KB, Corbett JJ: Idiopathic intracranial hypertension (pseudotumor cerebri): A reappraisal. Neurology 7:2–67, 2001.</p> |

1 mmHg = 13.8 mmH₂O. Shunt surgery (V.P. Shunt) was introduced in 1949. L.P. Shunt for IIIH was introduced in 1971.

Incidence

The prevalence is approximately 1 case / 100,000 women but increases to 13 cases / 100,000 women of ages 20 to 44 years who are 10% above ideal body weight and 19 cases / 100,000 women of ages 20 to 44 years who are obese 20% above ideal body weight.

Most studies demonstrated an age of onset between 11 and 58 years, with a mean of approximately 30 years.

Men are affected less frequently. The incidence is 0.3 cases / 100,000 men but increases to 1.5 cases / 100,000 obese men 20% above ideal body weight. Female – to – male ratios are approximately 4.3:1 to 8:1.

Pathophysiology

Mostly unclear.

Relative resistance to absorption of CSF across arachnoid villi is widely presumed.

Other theories support an abnormality in cerebral circulation which causes an increase in the brain water content which leads to increased ICP resulting in papilloedema.

Disease is most commonly associated with obese women. Obesity causes increase in the intra-abdominal pressure increasing cardiac filling pressure leading to impeded venous return from brain to heart which produces an increased venous pressure and increased intracranial pressure.

Clinical Presentation

Headache and visual obscuration is the most common symptoms. Sometimes the patients have pulsatile tinnitus and numbness can also occur. Papilledema is a criterion for the condition, is observed for virtually all patients with IIIH and is the most important sign. Abducens palsy, a false localizing sign thought to be attributable to traction of the VIth cranial nerve resulting from intracranial hypertension, is observed in approximately 20% of cases. Patients with IIIH have traditionally been thought to have slit ventricles, but a review of computed tomographic findings with IIIH demonstrated slit – like ventricles for only 11%; enlarged optic nerve sheaths (47%) and empty sella syndrome (46%) were more common. On L. P manometry, pressure of greater than 250 mm H₂O (18.11 mmHg), measured with the patient relaxed, in the lateral decubitus position, is one of the modified Dandy criteria. The most significant sequela of IIIH is blindness or permanent visual impairment caused by prolonged papilloedema with secondary optic atrophy. Because visual loss is usually insidious, patients may be nonchalant regarding vision testing and follow-up monitoring until irreversible damage to the optic nerve occurs.

Treatment

The treatment goal is to preserve optic nerve function while managing the increased ICP. Treatment indicated when there is severe intractable headache and evidence of progressive decrease in visual acuity. Cessation of the causative agents, weight reduction, carbonic anhydrase inhibitors and corticosteroids are the main stay of the medical treatment.

Surgical options include venticulo peritoneal shunt, lumbo peritoneal shunt and optic nerve sheath fenestration.

stration.

Anecdotal reports of success suggested that it was a curative procedure, as long as the shunt functioned properly. A multicenter review of the outcomes of shunting showed that the vision of most patients either improved or stabilized postoperatively. The finding that many optic nerve sheath fenestrations fail within 1 year, as well as mounting evidence of serious complications has proved LP shunting as the favored surgical treatment option.

MATERIAL AND METHODS

A total of 35 patients were diagnosed as IHH according to the Modified Dandy's criteria in our department from August 2007 to October 2012. An extensive literature review of IHH and related conditions was performed. The history of and rationale for the diagnosis and medical and surgical approaches to treatment are reviewed. Outcome of the patients' with L.P shunt is observed.

Surgical Procedure

The patient is placed in the lateral position with his/her knees bend. The surgery is performed in G.A. Under complete aseptic measure a 3-4 cm skin incision is given between the spinous process of L₃ – L₄ or L₄ – L₅. A Tuohy needle can be inserted in the midline after the paraspinous incision. The head end of the table is temporarily elevated 30° to increase the pressure in the lumbar subarachnoid space. A fourteen-gauge Tuohy needle is inserted into the lumbar subarachnoid space with the bevel – pointed cephalad (Fig. 1, 2). The lumbar end of the catheter is passed through the Tuohy needle. The operating table is tilted back to the normal position. The needle is withdrawn over the catheter. A small incision is made in the flank and the subcutaneous catheter passer with the obturator in place is passed through the flank incision. The obturator is removed and the distal end of the peritoneal catheter is inserted into the lumbar opening of the subcutaneous catheter passer. The subcutaneous catheter passer is withdrawn over the catheter leaving the flank portion in place. A small skin incision is made 2 cm below the umbilicus and 3 cm away from the midline. The subcutaneous catheter passer with the obturator in place is inserted from the abdominal incision to the flank incision. The obturator is removed and the peritoneal end is inserted into the flank opening of the catheter passer. The catheter is passed through the passer. The catheter is inserted into the peritoneal cavity under direct vis-

ion. The chamber is anchored by stitching it to prevent shunt dislodgement. After homeostasis all the wounds are closed in layers and aseptic bandaging is done.



Fig. 1: Steps of Operative Procedures Lateral Posterior of patient lumbar end of catheter inserted it L₃₋₄ posterior.



Fig. 2: Steps of Operative Procedures Lateral Posterior of patient lumbar end of catheter inserted it L₃₋₄ posterior.

RESULTS

Sex Incidence

This study was descriptive study in which we included 35 patients, 30 females and 5 males.

Age Incidence

Age ranging from 20 years to 45 years who presented

to us from the outdoor department of Lahore General Hospital, Lahore from August 2007 to October 2012.




Fig. 3: No. of Patients with Different Age Range.




Fig. 4: Sex Incidence.

In all of our patients Fundoscopy was done which revealed papilloedema in all the 35 (100%) patients, L.P manometry revealed 16 (40%) patients had severe and fulminant opening CSF pressures with values of more than 400 mmH₂O. while in 21 (60%) patients opening CSF pressure was 260 to 400 mmH₂O. At the same time CSF cytology and biochemistry was done revealing normal reports (Table 1).

C.T Scan brain plain and with I/V contrast, MRI brain plain and with I/V contrast and MRV of all the patients were performed. Most of the CT scans brain and MRI brain revealed normal study except in 16




Fig. 5: No. of Patients visited in Different Years.



Fig. 6a: Pre-operative fundus (Papilloedema).




Fig. 6b: Post-operative fundus (after 2 months).

Table 1: CSF Pressure and Number of Patients.

| CSF Pressure | | Patients | |
|--------------------|-----------|----------|------------|
| mmH ₂ O | mmHg | No | Percentage |
| More than 400 | 29 | 16 | 40 |
| 260 – 400 | 18.8 – 29 | 21 | 60 |
| Total | | 35 | 100 |

1 mmHg = 13.8 mmH₂O




Fig. 7a: C.T Scan brain plain (Slit like ventricles).

(40%) patients showing slit – like ventricles. MRV of all the patients showed that the venous sinuses were patent. Obesity was seen in 28 (80%) patients.




Fig. 7b: M.R.V showing patent dural sinuses.

Initially all the patients were offered medical treatment but due to failure of the medical treatment, they underwent L.P Shunt procedure.


Treatment policy of idiopathic intracranial hypertension, include neuroimaging (CT Scan Brain, MRI Brain, MRV), L.P manometry in lateral decubitus position, introduction of touhy needle into L₃ – L₄ space, catheter is directed upwards, CSF cytology is sent, mostly L.P Shunt is done via 2 incisions, post operative X-Rays is done in these patients.

Post operatively, X-Ray abdomen lateral and A.P views were performed to ensure the proper placement of the L.P shunt.


Fig. 9: Post operative X-rays showing placement of L.P shunt.



DIAGNOSIS



TREATMENT



OUTCOME

With the L.P shunt in all the 35 (100%) patients, headache was relieved. In 28 (80%) patients the visual symptoms resolved completely while 7 (20%) of the patients there was only partial improvement. The visual improvement in our patients depended upon the pre operative visual status of the patients, as some patients presented to us late.

Shunt complications included two (0.7%) cases of shunt dislodgement and one (0.35%) case of shunt over drainage.

DISCUSSION

Two goals must be considered when managing patients with idiopathic intracranial hypertension: prevention of visual loss and resolution of symptoms. Presence of severe visual loss (20/40 or worse) in one or both eyes at time of initial examination is one of the indications for surgery. In one of the case report Levent Sinan Bir et al visual acuity was 20/100 in the right eye and 5/100 in the left eye on admission. It is estimated that up to 17 percent of patients with IHH will progress to develop permanent visual loss. The final visual outcome in fulminant IHH is variable but, up to half of the patients, could become totally blind. Mensah et al. reported that patients with marked visual field constriction and severe visual acuity loss at the time of onset of the IHH showed only partial response to therapy with diuretics and steroids and these patients have suffered clinically malignant course with rapid progression to near blindness. Malomo et al. reported a case with a 4 – week history of persistent of IHH with visual loss and deafness that had a good response to the nonoperative treatments; however, Kidron and Pomeranz reported two cases with malignant IHH and one of these patients underwent lumboperitoneal shunt operation. In fact, it is not well known about malignant form of IHH, and there is no obvious explanation of the disastrous outcome in these patients, but, in agreement with occasional reports in the literature, it is strongly suggested not to squander time so as to protect the patient's visual acuity.

While in our study In 28 (80%) patients the visual symptoms resolved completely while 7 (20%) of the patients there was only partial improvement, although in some patients presence of visual symptoms were for a longer period of time, even than the result visual improvement after L. P. Shunt in our study is very much comparable to the international studies.

At present, no prospective, randomized, clinical

trials have compared the outcomes of these different therapies. Therefore, no procedure has been proven to be most efficacious.

Skau M et al, showed that optic nerve fenestration may prevent further visual loss, and has also helped relieve headache in up to one thirds of patients while with L.P Shunt there was improvement in headache in more than two third of the patients. Where as in our study 100% of the patients got relief from the headache symptoms. However, up to 33% of patients receiving fenestration who demonstrates visual improvement initially may manifest later deterioration in visual function.

In a study by Spoor TC et al, it was shown that cerebrospinal fluid shunting may be beneficial in treating acute visual loss and symptoms of intractable headache. Although considered the superior treatment for headache relief, shunting also significantly improved or stabilized visual function (Burgett RA et al). The same is proved in our study. Baker et al. recommended shunting for intractable headaches in the setting of progressive visual loss.

So, we recommend L.P Shunt to be performed as early as the patient is diagnosed.

CONCLUSION

Idiopathic intracranial hypertension is the diagnosis of exclusion. Medical therapy has a very little role in relieving signs and symptoms of this disease. L.P Shunt should be the treatment option in IHH.

Address for Correspondence:

Dr. Amir Aziz

*Senior Registrar, Neurosurgery Unit II
PGMI / Lahore General Hospital, Lahore*

Cell: 0333-6101244

REFERENCES

1. Ahlskog JE, O'Neill BP. Pseudotumor cerebri. *Ann Intern Med* 1982; 97: 249–256.
2. Baker RS, Carter D, Hendrick EB, Buncic JR. Visual loss in pseudotumor cerebri of childhood: A follow-up study. *Arch Ophthalmol* 1985; 103: 1681–1686.
3. Banta JT, Farris BK. Pseudotumor cerebri and optic nerve sheath decompression. *Ophthalmology* 2000; 107: 1907–1912.
4. Bartynski WS, Valliappan S, Uselman JH, Spearman MP. The adult radiographic shuntogram. *AJNR Am J Neuroradiol* 2000; 21: 721–726.
5. Bedford THB. The effect of increased intracranial ven-

- ous pressure on the pressure of the cerebrospinal fluid. *Brain* 1935; 58: 427–447.
6. Bell SM, Schreiner CM, Resnick E, Vorhees C, Scott WJ Jr. Exacerbation of acetazolamide teratogenesis by amiloride and its analogs active against Na⁺ / Hexchangers and Nachannels. *Reprod Toxicol* 1997; 11: 823–831.
 7. Billson FA, Hudson RL. Surgical treatment of chronic papilledema in children. *Br J Ophthalmol* 1975; 59: 92–95.
 8. Biousse V, Newman NJ, Lessell S. Audible pulsatile tinnitus in idiopathic intracranial hypertension. *Neurology* 1998; 50: 1185–1186.
 9. Birdwell BG, Yeager R, Whitsett TL. Pseudotumor cerebri: A complication of catheter – induced subclavian vein thrombosis. *Arch Intern Med* 1994; 154: 808–811.
 10. Blaw ME. Associated and idiopathic intracranial hypertension in children. *Postgrad Med* 1971; 50: 191–195.
 11. Boussier MG. Cerebral venous thrombosis: Diagnosis and management. *J Neurol* 2000; 247: 252–258.
 12. Brazis PW, Lee AG. Elevated intracranial pressure and pseudotumor cerebri. *Curr Opin Ophthalmol* 1998; 9: 27–32.
 13. Brockmeier B, Burbach H, Runge M, Altenkirch H. Raised intracranial pressure in chronic respiratory disease. *Lancet (letter)* 1997; 349: 883.
 14. Brodsky MC, Vaphiades M. Magnetic resonance imaging in pseudotumor cerebri. *Ophthalmology* 1998; 105: 1686–1693.
 15. Brouman ND, Spoor TC, Ramocki JM. Optic nerve sheath decompression for pseudotumor cerebri. *Arch Ophthalmol* 1988; 106: 1378–1383.
 16. Burde RM, Karp JS, Miller RN. Reversal of visual deficit with optic nerve decompression in long – standing pseudotumor cerebri. *Am J Ophthalmol* 1984; 77: 770–771.
 17. Burgett RA, Purvin VA, Kawasaki A. Lumboperitoneal shunting for pseudotumor cerebri. *Neurology* 1997; 49: 734–739.
 18. Campos SP, Olitsky S. Idiopathic intracranial hypertension after l-thyroxine therapy for acquired primary hypothyroidism. *Clin Pediatr* 1995; 34: 334–337.
 19. Cantu C, Barinagarrementeria F. Cerebral venous thrombosis associated with pregnancy and puerperium: Review of 67 cases. *Stroke* 1993; 24: 1880–1884.
 20. Capobianco DJ, Brazis PW, Cheshire WP. Idiopathic intracranial hypertension and seventh nerve palsy. *Headache* 1997; 37: 286–288.
 21. Capriles LF. Intracranial hypertension and iron – deficiency anemia. *Arch Neurol* 1963; 9: 147–153.
 22. Carlow TJ, Glaser JS. Pseudotumor cerebri syndrome in systemic lupus erythematosus. *JAMA* 1974; 228: 197–200.
 23. Chang D, Nagamoto G, Smith WE. Benign intracranial hypertension and chronic renal failure. *Cleve Clin J Med* 1992; 59: 419–422.
 24. Ch'ien LT. Intracranial hypertension and sulfamethoxazole. *N Engl J Med (letter)* 1976; 283: 47.
 25. Chiu AM, Chuenkongkaew WL, Cornblath WT, Trobe JD, Digre KB, Dotan SA, Musson KH, Eggenberger ER. Minocycline treatment and pseudotumor cerebri syndrome. *Am J Ophthalmol* 1998; 126: 116–121.
 26. Chumas PD, Armstrong DC, Drake JM, Kulkarni AV, Hoffman HJ, Humphreys RP, Rutka JT, Hendrick EB. Tonsillar herniation: The rule rather than the exception after lumboperitoneal shunting in the pediatric population. *J Neurosurg* 1993; 78: 568–573.
 27. Chumas PD, Kulkarni AV, Drake JM, Hoffman HJ, Humphreys RP, Rutka JT. Lumboperitoneal shunting: A retrospective study in the pediatric population. *Neurosurgery* 1993; 32: 376–383.
 28. Chutarian AM, Gold AP, Braun CN. Benign intracranial hypertension and Bell's palsy. *N Engl J Med* 1977; 296: 1214–1215.
 29. Cognard C, Casasco A, Toevi M, Houdart E, Chiras J, Merland JJ. Dural arteriovenous fistulas as a cause of intracranial hypertension due to impairment of cranial venous outflow. *J Neurol Neurosurg Psychiatry* 1998; 65: 308–316.
 30. Cohen DN. Intracranial hypertension and papilledema associated with nalidixic acid. *Am J Ophthalmol* 1973; 76: 680–682.
 31. Comabella M, Montalban J, Lozano M, Codina A. Lhermitte's sign in pseudotumor cerebri. *J Neurol* 1995; 242: 610–611.
 32. Condulis N, Germain G, Charest N, Levy S, Carpenter TO. Pseudotumor cerebri: A presenting manifestation of Addison's disease. *Clin Pediatr* 1997; 36: 711–713.
 33. Corbett JJ: Problems in the diagnosis and treatment of pseudotumor cerebri. *Can J Neurol Sci* 1983; 10: 221–229.
 34. Corbett JJ, Thompson HS. The rational management of idiopathic intracranial hypertension. *Arch Neurol* 1989; 46: 1049–1051.
 35. Corbett JJ, Nerad JA, Tse DT, Anderson RL. Results of optic nerve sheath fenestration for pseudotumor cerebri: The lateral orbitotomy approach. *Arch Ophthalmol* 1988; 106: 1391–1397.
 36. Corbett JJ, Savino PJ, Thompson HS, Kansu T, Schatz NJ, Orr LS, Hopson D. Visual loss in pseudotumor cerebri: Follow-up of 57 patients from 5 to 41 years and a profile of 14 patients with permanent severe visual loss. *Arch Neurol* 1982; 39: 461–474.
 37. Couban S, Maxner CE. Cerebral venous sinus thrombosis presenting as idiopathic intracranial hypertension. *Can Med Assoc J* 1991; 145: 657–659.
 38. Cushing H, Noleson A. Notes on a series of intracranial tumor and conditions simulating them: Tumor suspects; tumors unverified; tumors verified. *Arch Neurol Psych* 1923; 10: 605–668.
 39. Dandy WE. Intracranial pressure without brain tumor:

- Diagnosis and treatment. *Ann Surg* 1937; 106: 492–513.
40. Davidoff LM, Dyke CG. Hypertensive meningeal hydrops: A syndrome frequently following infection in the middle ear or elsewhere in the body. *Am J Ophthalmol* 1937; 20: 908–927.
 41. Davidson SI. A surgical approach to plerocephalic disc edema. *Trans Ophthalmol Soc U K* 1969; 89: 669–690.
 42. Davies G, Zilkha KJ. Decompression of the optic nerve in benign intracranial hypertension. *Trans Ophthalmol Soc U K* 1976; 96: 427–429.
 43. de Wecker L: On incision of the optic nerve in cases of neuroretinitis, in Fourth International Ophthalmological Congress: August, 1872. London, Savill Edwards, 1873: pp 11–14.
 44. Digre KB, Corbett JJ. Idiopathic intracranial hypertension (pseudotumor cerebri): A reappraisal. *Neurology* 2001; 7: 2–67.
 46. Donaldson JO. Pathogenesis of pseudotumor cerebri syndromes. *Neurology* 1981; 31: 877–880.
 47. Durcan FJ, Corbett JJ, Wall M. The incidence of pseudotumor cerebri: Population studies in Iowa and Louisiana. *Arch Neurol* 1988; 45: 875–877.
 48. Eggenberger ER, Miller NR, Vitale S. Lumboperitoneal shunt for the treatment of pseudotumor cerebri. *Neurology* 1996; 46: 1524–1530.
 49. Eisenberg HM, McComb JG, Lorenzo AV. Cerebrospinal fluid overproduction and hydrocephalus associated with choroid plexus papilloma. *J Neurosurg* 1974; 40: 381–385.
 50. Fischer EG, Welch K, Shillito J. Syringomyelia following lumboperitoneal shunting for communicating hydrocephalus: Report of three cases. *J Neurosurg* 1977; 47: 96–100.
 51. Fishman RA. The pathophysiology of pseudotumor cerebri: An unsolved puzzle. *Arch Neurol* 1984; 41: 257–258.
 52. Fishman RA. *Cerebrospinal Fluid in Diseases of the Nervous System*. Philadelphia, W.B. Saunders Co., 1992.
 53. Foley J. Benign forms of intracranial hypertension: “Toxic” and “otitic” hydrocephalus. *Brain* 1955; 78: 1–41.
 54. Fujiwara S, Sawamura Y, Kato T, Abe H, Katusima H. Idiopathic intracranial hypertension in female homozygous twins. *J Neurol Neurosurg Psychiatry* 1997; 62: 652–654.
 55. Galbraith JEK, Sullivan JH. Decompression of the periorbital meninges for relief of papilledema. *Am J Ophthalmol* 1973; 76: 687–692.
 56. Gardner K, Cox T, Digre KB. Idiopathic intracranial hypertension associated with tetracycline use in fraternal twins: Case reports and review. *Neurology* 1995; 45: 6–10.
 57. Gass A, Barker GJ, Riordan – Eva P, MacManus D, Sanders M, Tofts PS, McDonald WI, Moseley IF, Miller DH. MRI of the optic nerve in benign intracranial hypertension. *Neuroradiology* 1996; 38: 769–773.
 58. Getenet JC, Croisile B, Vighetto A, Grochowicki M, Goudable B, Aimard G, Trillet M. Idiopathic intracranial hypertension after ofloxacin treatment. *Acta Neurol Scand* 1993; 87: 503–504.
 59. Gettelfinger DM, Komen E. Superior sagittal sinus thrombosis. *Arch Neurol* 1977; 34: 2–6.
 60. Gideon P, Sorensen PS, Thomsen C, Stahlberg F, Gjeris F, Henriksen O. Increased brain water self-diffusion in patients with idiopathic intracranial hypertension. *AJNR Am J Neuroradiol* 1995; 16: 381–387.
 61. Giles C, Soble A. Intracranial hypertension and tetracycline therapy. *Am J Ophthalmol* 1971; 72: 981–982.
 62. Giuseffi V, Wall M, Siegel PZ, Rojas PB. Symptoms and disease associations in idiopathic intracranial hypertension (pseudotumor cerebri): A case-control study. *Neurology* 1991; 41: 239–244.
 63. Goh KY, Schatz NJ, Glaser JS. Optic nerve sheath fenestration for pseudotumor cerebri. *J Neuroophthalmol* 1997; 17: 86–91.
 64. Greer M. Benign intracranial hypertension: Part I—Mastoiditis and lateral sinus obstruction. *Neurology* 1961; 12: 472–476.
 65. Greer M. Management of benign intracranial hypertension (pseudotumor cerebri). *Clin Neurosurg* 1968; 15: 161–174.
 66. Guy J, Johnston PK, Corbett JJ, Day AL, Glaser JS. Treatment of visual loss in pseudotumor cerebri associated with uremia. *Neurology* 1990; 40: 28–32.
 67. Halbach VV, Hieshima GB, Higashida RT, Reicher M. Carotid cavernous fistulae: Indications for urgent treatment. *AJR Am J Roentgenol* 1987; 149: 587–593.
 68. Hamed LM, Glaser JS, Schatz NJ, Perez TH. Pseudotumor cerebri induced by danazol. *Am J Ophthalmol* 1989; 107: 105–110.
 69. Hannerz J, Greitz D, Ericson K. Is there a relationship between obesity and intracranial hypertension? *Int J Obes Relat Metab Disord* 1995; 19: 240–244.
 70. Hart A, David K, Powell M. The treatment of “acquired tonsillar herniation” in pseudotumor cerebri. *Br J Neurosurg* 2000; 14: 563–565.
 71. Herzau V, Baykal HE. Long – term outcome of optic nerve sheath fenestration in pseudotumor cerebri (in German). *Klin Monatsbl Augenheilkd* 1998; 213: 154–160.
 72. Horton JC, Seiff SR, Pitts LH, Weinstein PR, Rosenblum ML, Hoyt WF. Decompression of the optic nerve sheath for vision – threatening papilledema caused by dural sinus occlusion. *Neurosurgery* 1992; 31: 203–212.
 73. Howman – Giles R, Uren RG, Johnston I. Cerebrospinal fluid physiology, clearance flow studies, and cerebrospinal fluid shunt studies, in Murray IPC, Ell PJ (eds): *Nuclear Medicine in Clinical Diagnosis and Treatment*. Edinburgh, Churchill Livingstone, 1998.
 74. Huseman CA, Torkelson RD. Pseudotumor cerebri following treatment of hypothalamic and primary hypothyroidism. *Am J Dis Child* 1984; 138: 927–931.